Trial Profile
An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With HER2+ Breast Cancer Treated With Neratinib With or Without Trastuzumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Diphenoxylate/atropine (Primary) ; Loperamide (Primary) ; Neratinib (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions
- 06 Jan 2023 Status changed from active, no longer recruiting to completed.
- 14 Feb 2022 Planned number of patients changed from 23 to 11.
- 14 Feb 2022 Status changed from recruiting to active, no longer recruiting.